Phoenix Life
Announces Annual Financial Report Filings for 2015 and
2016
DENVER, CO
March 14, 2019 -- InvestorsHub NewsWire
-- Phoenix
Life Sciences International Limited (OTC: PLSI) ("Phoenix Life", the
"Company"), an international adaptive healthcare solutions company,
today announced that it has filed its Form 10-K Annual Reports,
including audited financial reports, with the Securities and
Exchange Commission ("SEC")
for the 2015 and
2016 fiscal years as part of the merger and consolidation completed
at the end of 2018.
Phoenix
Life was created through a consolidation of multiple domestic and
international businesses. As final audits are being
completed for the 2017 and 2018 fiscal years, corresponding 10-K
Annual Reports will likewise be filed, providing prospective and
current shareholders with current reporting.
Moving forward,
Phoenix Life intends to maintain a fully reporting status with the
SEC. This reporting status combined with OTC Markets requirements
for maintaining an OTCQB listing are intended to provide the
investing public with full transparency and greater market
liquidity.
Following
completion of bringing the Company current in its reporting,
Phoenix Life intends to complete a significant capital placement to
fund out company operations in the United States, Australia and the
South Pacific, including Vanuatu and subsequently apply for listing
on the NASDAQ.
"Phoenix Life is
committed to maintaining the high level of corporate and financial
disclosures required to provide existing and potential shareholders
with full transparency, while providing greater access to capital
for the Company and greater levels of market liquidity for our
investors," said Martin Tindall, CEO and
Founder of Phoenix Life.
The Company is
quickly advancing its international expansion efforts and just
announced the groundbreaking of the first of a National Network of
Community Clinics and Dispensing Pharmacies for the treatment of
diabetes in the Republic of Vanuatu last week. "It is great to see
Phoenix Life's milestones being achieved consistently and we look
forward to achieving much more in 2019 and beyond," continued
Tindall.
To learn more about
Phoenix Life Sciences International, please
visit https://phoenixlife.co/.
###
About Phoenix
Life Sciences International Limited
Phoenix Life
Sciences International Limited is an adaptive healthcare solutions
company. Our business is to advance research and integrate programs
and manufacturing of products that target and treat diabetes, pain,
cancer, and address psychological, gastrointestinal, autoimmune,
neurological and sleep disorders. We strive to create partnerships
and integrate these programs for human health into communities
worldwide as part of our Global Health Initiative.
FORWARD-LOOKING
STATEMENTS
Information
contained in this press release regarding Phoenix Life Sciences
International, Limited and its subsidiaries, (the "Companies") may
constitute forward-looking statements or statements which may be
deemed or construed to be forward-looking statements. The words
"plan", "forecast", "anticipates", "estimate", "project", "intend",
"expect", "should", "believe," and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to, known and unknown risks,
uncertainties and other factors which could cause the Company's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in the Company's filings with the
U.S. Securities and Exchange Commission. All forward-looking
statements attributable to the Companies herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. The Companies disclaim any obligation to update
forward-looking statements contained in this press release, except
as may be required by law.
FOOD AND DRUG
ADMINISTRATION (FDA) DISCLOSURE
These statements
have not been evaluated by the FDA and therefore the products sold
by Phoenix Life Sciences International are not available in the
U.S.
LEGAL
DISCLOSURE
Phoenix Life
Sciences International does not sell or distribute any products in
the United States that are in violation of the United States
Controlled Substances Act (US.CSA). This company does not grow,
sell, and distribute cannabis-based products in the United States
and is solely involved with the legal distribution of medical
cannabis-based products within certain international markets
outside of the United States.
Investor
Contact:
Phone:
1.888.717.5655 or international +1.720.699.7222
E-mail:
investor.relations@phoenixlife.co
Media
Contact:
Kathryn
Reinhardt
CMW
Media
Kathryn@cmwmedia.com
619-972-3089